Repligen Corp. - רווח נקי למניה אחת בשנים עשר החודשים האחרונים RGEN

Repligen Corporation (RGEN) is scaling its bioprocessing capabilities through alliances with pharma behemoths and mergers with startups. High-margin revenue is driven by the scalable production of biopharmaceutical consumables. The annual growth in EPS TTM illustrates the actual business expansion, where the -807.90 indicator expresses the state of the metric. The company is currently navigating a cyclical bottom, awaiting a recovery in demand for biopharmaceutical components.

Year-over-year (YoY) EPS growth (TTM) measures the rate of change in net income per share over a rolling year, reflecting the business's ability to generate additional income for shareholders. By analyzing the percentage dynamics of EPS YoY TTM, an investor can see the impact of demand for biopharma and gene therapy consumables on the capitalization of Repligen Corporation (RGEN) within the current macroeconomic environment.